Fluticasone Propionate + Salmeterol

[SDL] Fluticasone Propionate & Salmeterol [Seretide Evohaler] Inhalation Aerosol, Fluticasone Propionate 50 mcg/dose + Salmeterol 25 mcg/dose (120 inhalations), Fluticasone Propionate 125 mcg/dose + Salmeterol 25 mcg/dose (120 inhalations), Fluticasone Propionate 250 mcg/dose + Salmeterol 25 mcg/dose (120 inhalations)

[SDL] Fluticasone Propionate & Salmeterol [Seretide Accuhaler] Inhalation Powder, Fluticasone Propionate 100 mcg/dose + Salmeterol 50 mcg/dose (60 inhalations), Fluticasone Propionate 250 mcg/dose + Salmeterol 50 mcg/dose (60 inhalations), Fluticasone Propionate 500 mcg/dose + Salmeterol 50 mcg/dose (60 inhalations)

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

08/02/2023 Inhaled corticosteroids with long-acting beta₂ agonists for treating asthma>

[R] The Ministry of Health’s Drug Advisory Committee has recommended the following inhaled corticosteroid/long-acting beta₂ agonist (ICS/LABA) inhalers for inclusion on the MOH Standard Drug List (SDL) for treating asthma in view of acceptable clinical and cost-effectiveness:

• Fluticasone furoate/vilanterol (Relvar Ellipta) 100/25 mcg (30 inhalations) and 200/25 mcg (30 inhalations) inhalation powder;

• Budesonide/formoterol (DuoResp Spiromax) 160/4.5 mcg (120 inhalations) and 320/9 mcg (60 inhalations) inhalation powder.

[R] The Committee has also recommended the following ICS/LABA inhalers for retention on the MOH SDL, in view of acceptable proposals from the companies:

• Fluticasone propionate/salmeterol (Seretide Accuhaler) 100/50 mcg (60 inhalations), 250/50 mcg (60 inhalations), 500/50 mcg (60 inhalations) inhalation powder;

• Fluticasone propionate/salmeterol (Seretide Evohaler) 50/25 mcg (120 inhalations), 125/25 mcg (120 inhalations), 250/25 mcg (120 inhalations) inhalation aerosol;

• Budesonide/formoterol (Symbicort Turbuhaler) 160/4.5 mcg (120 inhalations) inhalation powder;

• Budesonide/formoterol (Symbicort Rapihaler) 80/2.25 mcg (120 inhalations), 160/4.5 mcg (120 inhalations) inhalation aerosol.

[NR] Of note, Symbicort Turbuhaler 80/4.5 mcg, 320/9 mcg and Symbicort Rapihaler 80/4.5 mcg will be delisted with effect from 1 August 2023 due to discontinuation by the company.

The subsidy class and subsidy implementation dates (if applicable) for all ICS/LABA inhalers are provided in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration